LUN96-1
A Phase II Study of Paclitaxel (3-Hour Infusion and Bolus Doxorubicin in Recurrent or Refractory Small Cell Lung Cancer
Abstracts/Posters/Presentations:
- Sonpavde G, Ansari R, Einhorn L. A Phase II Trial of Bolus Doxorubicin and 3-Hour Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer: A Hoosier Oncology Group Trial. A Hoosier Oncology Group Trial LUN96-1. Accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.
Manuscripts/Articles:
- Sonpavde G, Ansari R, Walker P, Sciortino DF, Gabrys GT, Murdock A, Gonin R, Einhorn LH. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol. 2000 Feb;23(1):68-70. See abstract.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter